Townsquare Capital LLC Has $32.25 Million Stake in Zoetis Inc. (NYSE:ZTS)

Townsquare Capital LLC boosted its holdings in Zoetis Inc. (NYSE:ZTS - Free Report) by 19.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 197,962 shares of the company's stock after acquiring an additional 32,382 shares during the quarter. Townsquare Capital LLC's holdings in Zoetis were worth $32,254,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the business. Mission Wealth Management LP increased its holdings in shares of Zoetis by 2.0% during the fourth quarter. Mission Wealth Management LP now owns 2,938 shares of the company's stock valued at $479,000 after purchasing an additional 59 shares during the period. VeraBank N.A. lifted its position in Zoetis by 4.1% in the fourth quarter. VeraBank N.A. now owns 1,562 shares of the company's stock worth $254,000 after purchasing an additional 62 shares during the period. HUB Investment Partners LLC lifted its holdings in shares of Zoetis by 4.7% in the fourth quarter. HUB Investment Partners LLC now owns 1,373 shares of the company's stock valued at $224,000 after buying an additional 62 shares during the period. Procyon Advisors LLC lifted its stake in Zoetis by 1.4% during the fourth quarter. Procyon Advisors LLC now owns 4,712 shares of the company's stock valued at $768,000 after purchasing an additional 63 shares during the last quarter. Finally, Deseret Mutual Benefit Administrators boosted its holdings in Zoetis by 6.6% during the fourth quarter. Deseret Mutual Benefit Administrators now owns 1,045 shares of the company's stock worth $170,000 after buying an additional 65 shares in the last quarter. Institutional investors own 92.80% of the company's stock.

Remove Ads

Zoetis Stock Down 1.1 %

ZTS stock traded down $1.68 during midday trading on Tuesday, reaching $149.15. The company had a trading volume of 2,785,108 shares, compared to its average volume of 2,567,650. The company has a 50 day moving average of $161.51 and a two-hundred day moving average of $170.76. The company has a market capitalization of $66.55 billion, a P/E ratio of 27.27, a PEG ratio of 2.78 and a beta of 0.92. Zoetis Inc. has a 1 year low of $139.70 and a 1 year high of $200.33. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09.

Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.37 by $0.03. The firm had revenue of $2.32 billion during the quarter, compared to analysts' expectations of $2.30 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. On average, equities research analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be issued a dividend of $0.50 per share. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.34%. Zoetis's dividend payout ratio is currently 36.56%.

Wall Street Analysts Forecast Growth

ZTS has been the subject of a number of recent research reports. Stifel Nicolaus cut their price objective on Zoetis from $180.00 to $165.00 and set a "buy" rating for the company in a research report on Monday. Morgan Stanley reduced their target price on Zoetis from $243.00 to $238.00 and set an "overweight" rating for the company in a report on Friday, February 14th. Piper Sandler boosted their price objective on Zoetis from $200.00 to $205.00 and gave the stock an "overweight" rating in a report on Thursday, February 27th. Barclays raised their target price on shares of Zoetis from $242.00 to $244.00 and gave the stock an "overweight" rating in a report on Friday, February 14th. Finally, StockNews.com upgraded shares of Zoetis from a "hold" rating to a "buy" rating in a report on Friday, March 7th. One research analyst has rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of "Buy" and a consensus price target of $214.40.

Insider Buying and Selling

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $170.00, for a total transaction of $55,420.00. Following the transaction, the executive vice president now owns 15,781 shares in the company, valued at $2,682,770. This trade represents a 2.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Willie M. Reed sold 1,210 shares of the business's stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total transaction of $201,029.40. Following the completion of the sale, the director now owns 11,245 shares of the company's stock, valued at $1,868,244.30. The trade was a 9.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 1,862 shares of company stock worth $312,254. Corporate insiders own 0.16% of the company's stock.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.